Genetically Attenuated Nucleic Acid Vaccine
OwnerLaura SHACKELTON, Matthew KERNERinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerLaura SHACKELTON, Matthew KERNERinventors
Estimating the term…
The disclosed compositions and methods provide an approach for the rational development of a nucleic acid vaccine. Methods are disclosed to deliver a viral genome, and/or a representative or derivative of such, that is attenuated but can, when co-delivered with unreplicable compensatory translational tools to a host cell, initially generate phenotypically wild-type, genetically attenuated viruses which infect subsequent cells and elicit a relevant and robust immune response. However, progeny of this initial generation, lacking the compensatory tools delivered to the initial host cells, are both phenotypically and genetically attenuated, thereby compromised in their ability to induce disease.
A method of making a nucleic acid vaccine comprising:
A nucleic acid vaccine produced by a method comprising:
Dependencies are inferred from the claim text.